way 100135 has been researched along with sr141716 in 1 studies
| Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (sr141716) | Trials (sr141716) | Recent Studies (post-2010) (sr141716) |
|---|---|---|---|---|---|
| 143 | 0 | 34 | 2,229 | 60 | 631 |
| Protein | Taxonomy | way 100135 (IC50) | sr141716 (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.0069 | |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | 0.0081 | |
| Cannabinoid receptor 1 | Homo sapiens (human) | 0.0219 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.0069 | |
| Cannabinoid receptor 2 | Homo sapiens (human) | 2.4666 | |
| Cannabinoid receptor 1 | Mus musculus (house mouse) | 0.025 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.108 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.795 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Egashira, N; Fujioka, M; Fujiwara, M; Hasebe, N; Hayakawa, K; Hazekawa, M; Iwasaki, K; Liu, AX; Mishima, K; Nozako, M; Ogata, A | 1 |
1 other study(ies) available for way 100135 and sr141716
| Article | Year |
|---|---|
Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Temperature; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Dronabinol; Drug Administration Schedule; Drug Interactions; Drug Tolerance; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Piperidines; Pyrazoles; Rimonabant; Serotonin Antagonists; Time Factors | 2007 |